Preventx Hand Sanitizer To Begin Trial Launch At Wal-Mart Outlets
This article was originally published in The Tan Sheet
Executive Summary
Empyrean Biosciences launched Preventx Hand Sanitizer & Antiseptic Skin Protectant in a dozen Wal-Mart outlets for test marketing Aug. 1. The product will be sold in Phoenix, Ariz. area stores, followed by nine Columbus, Ohio outlets if the product meets the Wal-Mart sales criteria, which is to outsell 50% of other hand sanitizer products. In-store promotions and demonstrations will be provided by the company.
You may also be interested in...
Jergens Anti-Bacterial lotion
Prophylactic claims for product draw April 22 warning letter from FDA. Claims include "Your skin needs daily protection from...the bacteria and germs you encounter every day and...bonds to skin for germ protection." The agency states that "representatives for prophylactic antimicrobial barrier use...are not described in any of the rulemakings being considered under the [OTC] Review. Further, we are not aware of any substantial scientific evidence that Jergens Anti-Bacterial Antiseptic Lotion is generally recognized among scientific experts as safe and effective for these uses, and this product has not been marketed for a material time and to a material extent." As a result, the product, which contains benzalkonium chloride, is considered an unapproved new drug, according to FDA. Andrew Jergens is preparing a response. The agency sent a similar letter to Bristol-Myers Squibb in May 1998 for its Keri Anti-Bacterial Lotion ("The Tan Sheet" June 15, 1998, p. 3)
Keri Anti-Bacterial Hand Lotion prophylaxis claims cited in FDA warning letter.
BRISTOL KERI ANTI-BACTERIAL LOTION PROPHYLACTIC CLAIMS DRAW WARNING LETTER from FDA citing the antibacterial hand lotion as an unapproved new drug that may not be marketed in the U.S. without an approved NDA. Preventative indications for Bristol- Myers Squibb's Keri Anti-Bacterial Hand Lotion "do not qualify for evaluation under the ongoing OTC drug review being conducted by the FDA," the May 8 warning letter states. According to the agency, the product is intended for "repeated use on the hands by the general public and by health care professionals as an antiseptic/moisturizer and to remain on the skin to provide hours of continuous antimicrobial effectiveness against pathogenic microorganisms."
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC